Dr. Cate Varney @CateVarney

Associate Professor. UVA School of Medicine, Department of Family Medicine. Obesity Medicine Director, UVA Health. OM in Primary Care & after Bariatric Surgery. Charlottesville, VA Joined November 2019

Tweets

594
Followers

1K
Following

415
Likes

599

Dr. Cate Varney @CateVarney

2 months ago

@realDaveFeldman @gregmushen Yes, with some responsible controls to protect privacy of human trial data. Open data can accelerate discovery in health and allow independent verification of results. It also lets smaller institutions and startups build on work they didn’t directly fund.

0 1 1 269 0

View Details

Dr. Cate Varney @CateVarney

2 months ago

@MichaelAlbertMD @net_runner_ Look no further than the exponential rise of calls to Poison Control in mid-2021 followed by rapid acceleration from 2021-2024. They don’t differentiate between branded GLP1 and compounded but given the variable dosing of compounds, it’s a signal that shouldn’t be ignored.

0 0 0 19 0

View Details

Dr. Cate Varney @CateVarney

7 months ago

@Tellit007 @novonordisk @EliLillyandCo Traditional pharmacies (Medicare recipients) and Lilly Direct and TrumpRX (those without coverage).

0 0 1 57 0

View Details

Dr. Cate Varney @CateVarney

7 months ago

Thank you @novonordisk and @EliLillyandCo for bringing costs down! whitehouse.gov/fact-sheets/20…

1 0 3 318 0

View Details

Dr. Cate Varney @CateVarney

7 months ago

Obesity rates on the decline. @OMAsocial @ASMBS @ObesitySociety @uvahealthnews news.gallup.com/poll/696599/ob….

0 0 2 224 0

View Details

Dr. Cate Varney @CateVarney

8 months ago

Day 2 #OMSummit2025, OMA President, Dr. Harold Bays, presenting on the “Obesity Paradox”. @OMAsocial

0 0 2 219 0

View Details

Dr. Cate Varney @CateVarney

8 months ago

#OMSummit2025

Michael Albert, MD @MichaelAlbertMD

8 months ago

🚨 Primary Prevention Milestone in Heart Disease - - - Amgen just announced topline results from VESALIUS-CV (12,000 patients, 4.5 years follow-up): ➡️ Adding Repatha (evolocumab) to statins or other LDL-lowering therapy significantly reduced major CV events in adults without

9 43 139 16K 58

0 0 1 190 0

View Details

Dr. Cate Varney @CateVarney

8 months ago

Welcome to the #OMSummit25! I’ll be your course chair as we dive into topics related to obesity and cardiometabolic health. @OMAsocial

0 0 1 94 0

View Details

Michael Albert, MD @MichaelAlbertMD

8 months ago

I would argue that James Johnson and others have demonstrated that when insulin signaling is severely impaired—essentially reaching an “end state”—it drives a highly obesogenic physiological condition. In this context, the anabolic dominance of disrupted insulin pathways may potentially be counterbalanced by agents such as amylin and glucagon, which act through complementary mechanisms to mitigate the metabolic consequences of disturbed insulin action.

Eric Topol @EricTopol

8 months ago

More than 2 decades since GLP-1 drugs were introduced, we still don't know why people with diabetes lose about half as much weight as those without diabetes at the same dose nature.com/articles/s4136…

26 105 593 71K 144

1 2 15 4K 5

View Details

Dr. Cate Varney @CateVarney

8 months ago

Today, @PeteHegseth used "hot yoga" as a dismissive example of inadequate physical training while announcing new, more stringent fitness standards for U.S. military personnel. Invitation extended to him to join me @HotYogaCville to see the CV & strength & flexibility benefits!

0 0 2 66 0

View Details

Dr. Cate Varney @CateVarney

8 months ago

@OMAsocial just released the first in a series of learning modules for comprehensive obesity treatment. Although titled "Osteopathic Perspective", it is tailored for MD/DO/NP/PA/RN/RDs. Really proud of how this turned out! @ACOFP obesitymedicine.org/education/oste…

0 0 1 9 0

View Details

Dr. Cate Varney @CateVarney

a year ago

29news.com/2025/04/01/uva…

0 0 2 290 0

View Details

Salud America! @SaludAmerica

a year ago

Obesity can play a role in diabetes and cancer. Find out the latest in obesity prevention and management at our next webinar!🙏🏽 Register: bit.ly/scaleswebinar @UTHealthSAMDA @genentech @PsychoDietitian @StopWeightBias @CNTNguyenMD @CateVarney @KevinGendreau @GasolFndnUSA

0 3 5 530 0

View Details

Michael Albert, MD @MichaelAlbertMD

a year ago

Higher LDL-C levels driven by PCSK9 activity are associated with a ~1-year reduction in life expectancy at the population level. Conversely, enhanced LDL receptor function, such as that achieved with statins or PCSK9 inhibitors, is linked to improved longevity outcomes. These findings highlight the critical role of lipid management in population health and underscore the potential of therapies targeting PCSK9 (PCSK9 inhibitors) and LDL receptors (statins) to extend lifespan. For more details, see: PubMed: 33704808 PubMed: 38082436

1 5 14 2K 6

View Details

Dr. Cate Varney @CateVarney

2 years ago

@Slumdogsomil pmc.ncbi.nlm.nih.gov/articles/PMC10…

0 0 0 42 0

View Details

Dr. Cate Varney @CateVarney

2 years ago

@Slumdogsomil POUNDS LOST originally said “a calorie is a calorie”, but later when analyzing genetic variations, it demonstrated biochemical, behavioral, & psychosocial factors such as activity, sleep disturbance, & appetite may also modulate metabolic changes during dietary interventions.

2 0 4 239 0

View Details

Dr. Cate Varney @CateVarney

2 years ago

@jonbischke @MedicareGov @BevTchangMD @ObesityAction @STOPObesity @ObesitySociety @ObesityWeek @ObesityAdvocacy Here is a little bit clearer shot that you can zoom in for source information.

0 0 0 89 0

View Details

Dr. Cate Varney @CateVarney

2 years ago

If @MedicareGov covered obesity medications, it would make up 0.1% of the 2026 Medicare budget. What things do you see Medicare cover now that would be money better spent on obesity meds? Credit: @BevTchangMD (presenter) #ObesityWeek2024 @ObesityAction @STOPObesity